Meeting
2015 ASCO Annual Meeting
Single institution experience with 75 mg dose of erlotinib in Latin American patients with mutated metastatic non-small cell lung cancer.
Authors
Osvaldo Rudy Aren
Centro Internacional de Estudios Clínicos, Santiago, Chile
Osvaldo Rudy Aren , Ricardo Silva , Humberto Cerda , Jorge M Arancibia , Carlos Rojas , Mauricio Reyes , Rodrigo Andres Ascui , Patricia Banchero , Mauricio Emmanuel Burotto Pichun
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8075)
DOI
10.1200/jco.2015.33.15_suppl.8075
Abstract #
8075
Poster Bd #
399
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase II trial of lazertinib in epidermal growth factor receptor (EGFR) mutation-positive (M+), metastatic non-small cell lung cancer (NSCLC) patients with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (TKI) (KCSG LU20-15).
First Author: Min Hee Hong
Poster
2020 ASCO Virtual Scientific Program
RELAY+: Exploratory study of ramucirumab plus gefitinib in untreated patients (pts) with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell lung cancer (NSCLC).
First Author: Makoto Nishio
Poster
2017 ASCO Annual Meeting
Gefitinib as third-line re-challenge treatment in advanced NSCLC patients with EGFR activating mutation who benefited from first-line gefitinib treatment followed by second-line chemotherapy.
First Author: Yong Song
Poster
2014 ASCO Annual Meeting
A prospective, multicenter phase II trial of low-dose erlotinib monotherapy for patients with previously treated non-small cell lung cancer (NSCLC) with activating mutation of epidermal growth factor receptor (EGFR): Thoracic Oncology Research Group (TORG) 0911.
First Author: Yoshiro Nakahara